
Matricelf Ltd. — Investor Relations & Filings
Matricelf Ltd. is a preclinical-stage biotechnology company specializing in regenerative medicine and tissue engineering. The company develops a proprietary platform for creating fully autologous, patient-specific tissue implants. This technology combines a patient's induced Pluripotent Stem Cells (iPSCs) with a personalized, thermo-responsive hydrogel derived from their own extracellular matrix (ECM). The iPSCs are differentiated within this hydrogel to generate functional tissue. This autologous approach is designed to minimize the risk of immune rejection and provide a personalized, curative therapy. Matricelf's primary focus is on developing a one-time treatment for spinal cord injuries, aiming to bridge damaged tissue and restore lost function. The platform is also being explored for other conditions, including stroke, traumatic brain injury, and myocardial infarction.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| INVESTORS PRESENTATION | 2026-01-28 | English | |
| INVESTORS PRESENTATION | 2026-01-28 | Russian | |
| COMPANY'S PRESENTATION | 2024-09-08 | Hebrew (modern) | |
| COMPANY'S PRESENTATION | 2024-09-08 | Russian | |
| INVESTORS PRESENTATION | 2024-03-27 | English | |
| INVESTORS PRESENTATION | 2024-03-27 | Russian |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
2 filings
| |||||
| 13520625 | INVESTORS PRESENTATION | 2026-01-28 | English | ||
| 13520623 | INVESTORS PRESENTATION | 2026-01-28 | Russian | ||
|
2024
4 filings
| |||||
| 6468367 | COMPANY'S PRESENTATION | 2024-09-08 | Hebrew (modern) | ||
| 6468366 | COMPANY'S PRESENTATION | 2024-09-08 | Russian | ||
| 6470518 | INVESTORS PRESENTATION | 2024-03-27 | English | ||
| 6470517 | INVESTORS PRESENTATION | 2024-03-27 | Russian | ||
|
2023
2 filings
| |||||
| 6531143 | Corporate Presentation - February2023 | 2023-02-14 | English | ||
| 6531142 | Corporate Presentation - February2023 | 2023-02-14 | Russian | ||
|
2022
2 filings
| |||||
| 6478888 | INVESTORS PRESENTATION | 2022-03-16 | English | ||
| 6478886 | INVESTORS PRESENTATION | 2022-03-16 | Russian | ||
|
2021
2 filings
| |||||
| 6482020 | Opening of Trading On Sunday June 20, 2021, Appointment of a Market Maker | 2021-06-17 | Hebrew (modern) | ||
| 6481948 | Identifying Details of New Security: MATRICELF, MATRICELF.W1 | 2021-06-14 | Hebrew (modern) | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
CALIWAY BIOPHARMACEUTICALS CO., LTD.
Develops small-molecule therapeutics for medical aesthetics…
|
6919 | TW | Professional, scientific and te… |
|
CALIX LIMITED
Develops industrial carbon capture and sustainable mineral …
|
CXL | AU | Professional, scientific and te… |
|
CAMBIUM BIO LIMITED
Clinical-stage developer of cellular therapies for ophthalm…
|
CMB | AU | Professional, scientific and te… |
|
CAMBRIDGE COGNITION HOLDINGS PLC
Develops digital solutions and a platform for CNS clinical …
|
COG | GB | Professional, scientific and te… |
|
CanBas Co.,Ltd.
A clinical-stage biopharmaceutical company developing novel…
|
4575 | JP | Professional, scientific and te… |
|
Captor Therapeutics S.A.
Develops Targeted Protein Degradation therapies for cancer …
|
CTX | PL | Professional, scientific and te… |
|
Cardiff Oncology, Inc.
A clinical-stage biotech developing cancer therapies that i…
|
CRDF | US | Professional, scientific and te… |
|
Cardio Diagnostics Holdings, Inc.
Develops AI-powered epigenetic and genetic tests for early …
|
CDIO | US | Professional, scientific and te… |
|
Cardiol Therapeutics Inc.
Clinical-stage company developing anti-inflammatory therapi…
|
CRDL | CA | Professional, scientific and te… |
|
CASSAVA SCIENCES INC
Clinical-stage biotech developing treatments for Central Ne…
|
SAVA | US | Professional, scientific and te… |
Matricelf Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/6904/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=6904 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=6904 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=6904 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 6904}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Matricelf Ltd. (id: 6904)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.